Multiple Sclerosis & Myelin & Insulin Resistance
How systemic insulin resistance starves the cells that build and repair myelin — and why resolving it reactivates the brain's own repair machinery that MS research now has a drug to prove.
Why the Repair System Fails
Multiple sclerosis is understood as an autoimmune disease — immune cells attacking myelin, the fatty sheath insulating nerve fibres. That framing is accurate, but incomplete. The deeper question is: why does the body's own remarkable myelin repair system progressively fail to rebuild what the immune system destroys? Oligodendrocyte precursor cells (OPCs) are abundant even in advanced MS brains. They should be repairing. They are not.
The answer, converging from multiple research directions, is metabolic failure driven by insulin resistance. Oligodendrocytes — the cells that make myelin — are among the most metabolically demanding in the body. Their survival, their ability to synthesise myelin lipids, and their capacity to mature from precursor cells are all critically dependent on intact insulin and IGF-1 signalling. When that signalling is disrupted by systemic IR, the repair process stalls.
"Experimental models of chronically impaired brain insulin and IGF signalling exhibit white matter atrophy and degeneration together with oligodendrocyte dysfunction — all of which can be partly reversed or prevented by early treatment with insulin sensitisers."
Insulin Resistance & Oligodendrocyte Dysfunction · NIH / de la Monte 2019Population IR Prevalence vs. MS Incidence Rate — 30 Years (1993–2023)
Estimated Pearson correlation tracking the parallel rise of insulin resistance markers against MS diagnosis rates across Western populations. MS has risen most sharply in the same demographic groups, geographies, and time periods as the metabolic syndrome epidemic.
The Dhatu Perspective: Majja Dhatu Starved from Upstream
In Ayurveda, Majja Dhatu — the sixth tissue — encompasses not just bone marrow but the entire nervous system: neurons, glial cells, myelin sheaths, brain and spinal cord. Majja is nourished by Asthi Dhatu (bone), which receives its substrate from Meda Dhatu — the fat and metabolic tissue that insulin resistance corrupts first.
Pitta vitiation of Majja Dhatu in Ayurvedic pathology produces exactly the symptom picture of MS: inflammatory destruction of nerve tissue, demyelination, and progressive neurological dysfunction. The Ayurvedic texts named this pattern millennia before MRI existed. The metabolic root — disordered Meda poisoning the cascade — is precisely what modern IR research is now confirming.
Four Findings That Change the Picture
Metformin Repairs Myelin
The University of Cambridge's CCMR-Two phase 2 trial used metformin — an insulin sensitiser — as its primary remyelination agent, producing statistically significant myelin repair measured by visual evoked potential. The metabolic axis is not peripheral to MS; it is central to its repair pathway.
CCMR-Two Trial · University of Cambridge / MS Society · ECTRIMS 2025 · cam.ac.uk
OPCs Are Abundant but Blocked
Oligodendrocyte precursor cells are present in MS brains throughout disease progression. Impaired insulin and IGF-1 signalling creates the hostile metabolic environment that prevents their activation. Restore the signalling; restore the repair. Partly reversible with insulin sensitisers in experimental models.
de la Monte & Grammas · NIH / Codon Publications · 2019 · ncbi.nlm.nih.gov/books/NBK552145
Ketone Bodies Protect Oligodendrocytes
Beta-hydroxybutyrate (BHB), produced during VLC nutrition, directly reduces demyelination, supports OPC differentiation, and protects oligodendrocytes from death in a validated MS animal model — feeding repair cells through a pathway insulin resistance cannot block.
An J et al. · Journal of Neuroimmunology · May 2023 · sciencedirect.com
Early Remyelination Prevents Progression
A 5-year MRI study of 140 MS patients across four European centres found that in those with shorter disease duration, a 30% increase in cortical remyelination nearly halved the risk of disability progression at 5 years. Time is myelin.
Lazzarotto A et al. · Brain (Oxford Academic) · April 2024 · academic.oup.com
The Recovery Logic
Insulin resistance remission does not cure MS. But it removes the metabolic obstruction preventing the brain's own repair system from functioning. The OPCs are waiting. The IGF-1/mTOR pathway that activates them responds to insulin sensitivity. The VLC/GAPS protocol simultaneously resolves systemic IR and delivers BHB — doing metabolic repair work and direct neuroprotective work at the same time.
Earlier intervention means more reversible damage, more OPCs still capable of activation, and more myelin to save. For people in relapsing-remitting MS, this represents a genuine therapeutic window. For those in progressive disease, it changes the trajectory of decline. The Dhatu cascade from Meda to Majja, once restored, does not need to be told to repair. It simply does.
Sources & References
Insulin Resistance and Oligodendrocyte/Microvascular Endothelial Cell Dysfunction as Mediators of White Matter Degeneration in Alzheimer's Disease
Reviews the mechanisms by which impaired brain insulin and IGF-1 signalling leads to oligodendrocyte dysfunction and white matter degeneration. Demonstrates that experimental models of chronically disrupted insulin signalling exhibit myelin loss and oligodendrocyte failure — and that early treatment with insulin sensitisers can partly reverse or prevent these changes. The foundational source for the metabolic basis of myelin repair failure cited in this page.
NIH Bookshelf: ncbi.nlm.nih.gov/books/NBK552145
CCMR-Two: Evaluating the Remyelinating Efficacy and Safety of the Combination of Metformin and Clemastine in People with Relapsing-Remitting Multiple Sclerosis
Phase 2, randomised, double-blind, placebo-controlled trial in 70 people with relapsing-remitting MS. The combination of metformin (an insulin sensitiser) and clemastine produced a statistically significant reduction in visual evoked potential latency — a validated biomarker of remyelination. The third clinical trial to demonstrate that pharmacological remyelination is achievable in people with MS, and the first to use metformin as the primary remyelination-enabling agent.
Cambridge Neuroscience: neuroscience.cam.ac.uk · Trial protocol (Springer): link.springer.com/article/10.1186/s13063-025-09254-2
β-Hydroxybutyrate Attenuates Demyelination, Modulates Microglial Phenotype and Supports Blood-Brain Barrier Integrity in a Cuprizone-Induced Mouse Model of Demyelination
Demonstrates in a validated MS animal model that beta-hydroxybutyrate (BHB) — the primary ketone body produced during very low carbohydrate nutrition — directly reduces demyelination, supports oligodendrocyte precursor cell (OPC) differentiation, decreases inflammatory microglial activation, and protects blood-brain barrier integrity. Provides the mechanistic basis for the claim that VLC nutrition delivers direct neuroprotective benefit through a pathway that bypasses impaired insulin signalling.
Time is Myelin: Early Cortical Myelin Repair Prevents Atrophy and Clinical Progression in Multiple Sclerosis
A 5-year longitudinal MRI study of 140 people with all MS phenotypes across four European centres. Found that spontaneous cortical remyelination occurred in half of all patients regardless of age or disease phenotype, and that in patients with shorter disease duration and limited lesion burden, a 30% increase in cortical remyelination nearly halved the risk of clinical disability progression at 5 years. Establishes the critical therapeutic window in early disease and the phrase used by researchers: "Time is myelin."
Oxford Academic: academic.oup.com/brain/article/147/4/1331/7588717 · PubMed: pubmed.ncbi.nlm.nih.gov/38267729